NCI/NIH Antibody Engineering & CAR T Cell Development – Postdoctoral Fellowship
The Laboratory of Molecular Biology at the National Cancer Institute, NIH in Bethesda, Maryland, USA has an open postdoctoral fellow position. The laboratory focuses on identifying novel cancer targets including heparan sulfate proteoglycans and MHC associated peptides, and developing antibody engineering technologies for treating cancer. The successful candidate will be involved in isolation of antibodies using phage display and/or single B cell cloning technologies, and construction of CAR T cells, and testing of the CAR T cells using mouse tumor models.
Our recent papers related to CAR T cell development have been published in PNAS (https://www.ncbi.nlm.nih.gov/pubmed/28739923) and Gastroenterology (https://pubmed.ncbi.nlm.nih.gov/32060001/). Detailed information about our research program and publications can be accessed: https://ccr.cancer.gov/mitchell-ho
Candidates are expected to have completed, or be completing, a Ph.D. or M.D./Ph.D. with a strong publication record and expertise in molecular and cell biological techniques. Motivated candidates who are interested in innovative, high-impact laboratory research are encouraged to apply. A background in molecular biology, cell biology, immunology and/or cancer biology is required. Experience in T cell immunology or single B cell cloning is preferred. The position is available immediately.
Applications should be sent by e-mail to Dr. Mitchell Ho (email@example.com). Each application should consist of a cover letter describing your research experience and interests, curriculum vitae, bibliography, and contact information of three references (inclusion of your current mentor/supervisor is preferred).
This position is subject to a background investigation. The NIH is dedicated to building a diverse community in its training and employment programs.
Apply for NCI/NIH Antibody Engineering & CAR T Cell Development – Postdoctoral Fellowship
Already uploaded your resume? Sign in to apply instantly